Bal Pharma posts Q3 FY2023 profit at Rs. 59.16 lakhs
The company has reported total income of Rs.77.0791 crores during the period ended December 31, 2022 as compared to Rs.69.9191 crores during the period ended December 31, 2021.
The company has reported total income of Rs.77.0791 crores during the period ended December 31, 2022 as compared to Rs.69.9191 crores during the period ended December 31, 2021.
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
The company is proud to be at the forefront of promoting cancer awareness and hopes to make a positive impact on the lives of its employees
At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure
A pharma industry veteran with over three decades of experience in domestic as well as international markets
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
Company has provided Image Transmission and Reporting of Radiology Images and Selective Radiology Services (X-ray Tele Radiology Services) across all districts in the state of Tripura during the month of June, 2022 and operationalized its services at all the allocated places as on date.
He is a Chartered Accountant with more than 19 years of extensive experience
The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years
The company has reported total income of Rs. 781.40 crores during the period ended December 31, 2022
Subscribe To Our Newsletter & Stay Updated